Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 532523 | NSE Symbol : BIOCON | ISIN : INE376G01013 | Industry : Pharmaceuticals |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
03-Jan-2025	30-Jan-2025	Quarterly Results	BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31 2024 amongst other routine matters. Outcome of Board Meeting dated 30.01.2025 (As Per Bse Announcement Dated on 30.01.2025)
22-Jan-2025	27-Jan-2025	Private Placement Basis	BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/01/2025 ,inter alia, to consider and approve Raising of Funds through issuance of Commercial Papers (CPs) or through any other mode on private placement basis. Outcome of Board Meeting held on 27.01.2025 (As Per BSE Announcement Dated on 27/01/2025)
03-Oct-2024	30-Oct-2024	Quarterly Results	BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2024 inter alia to consider and approve Intimation for board meeting Unaudited Standalone and Consolidated Financial Results for quarter and half-year ended September 30, 2024 Outcome of Board Meeting dated October 30, 2024 (As Per BSE Announcement dated on 30.10.2024)
17-Jul-2024	08-Aug-2024	Quarterly Results	BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve approval of the un-audited financial results for the quarter ended 30.06.2024. Outcome of the Board Meeting held on 08.08.2024 (As Per BSE Announcement Dated on: 08/08/2024)
11-Jun-2024	11-Jun-2024	Change in Other Executives	Appointment of Interim CFO
10-Apr-2024	16-May-2024	Quarterly Results	BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2024 ,inter alia, to consider and approve Audited standalone and consolidated results and to consider recommendation of dividend, if any, amongst other routine matters. The Board has approved the appointment of Mr. Atul Dhawan as an Additional Director (Non Executive and Independent) of the Company w.e.f. May 16, 2024. Outcome of Board Meeting held on May 16, 2024 Outcome of Board meeting and Audited Financials Results for the financial year ended 31.03.2024 The Board recommended a final dividend at the rate of 10% i.e. Re. 0.50 per equity share, subject to the shareholders'' approval. (As Per BSE Announcement dated on 16.05.2024)
10-Jan-2024	08-Feb-2024	Quarterly Results	BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve Please find attached the Board Meeting Intimation for considering the Financial Results for Quarter ended December 31 2023. Outcome of Board Meeting (As Per BSE Announcement Dated on: 08/02/2024)
09-Oct-2023	10-Nov-2023	Quarterly Results	BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve un-audited standalone and consolidated financial results for the quarter and half year ended September 30 2023 amongst other routine matters. Outcome of Board Meeting and Financial Results for the quarter and half-year ended September 30, 2023 Outcome of Board meeting held on November 10, 2023 (As Per BSE Announcement Dated on 10.11.2023)
21-Jul-2023	10-Aug-2023	Quarterly Results	BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve the un-audited standalone and consolidated financial results for the quarter ended June 30 2023 BIOCON LIMITED has informed BSE about Board Meeting to be held on 10 Aug 2023 to consider financial statements for the period ended June 2023. Financial results. Outcome of Board Meeting Appointment of Director (As per BSE Announcement Dated on 10/08/2023) The appointment of Mr. Nicholas Robert Haggar as an Additional Director (category: Independent) on the Board of Biocon Limited is effective from September 01, 2023. (As Per BSE Announcement Dated on 01/09/2023)
20-Apr-2023	23-May-2023	Quarterly Results	BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 inter alia to consider and approve Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday May 23 2023 inter alia to approve and take on record the audited standalone and consolidated financial results of the Company for the quarter and financial year ended March 31 2023 and to consider recommendation of dividend if any amongst other routine matters. Final Dividend & Audited Results & A.G.M. (As per BSE Bulletin dated on 20/04/2023) The Board recommended a final dividend at the rate of 30% i.e. Rs. 1.50/- per equity share of face value of Rs. 5/- each for the financial year ended March 31, 2023, subject to shareholders' approval at the ensuing Annual General Meeting ('AGM'). Pursuant to Regulation 42 of SEBI Listing Regulations, the Company has fixed Friday, July 7, 2023 as the record date for determining entitlement of members to final dividend for the financial year ended March 31, 2023. The dividend will be paid on or before September 8, 2023. Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ('SEBI Listing Regulations') we wish to inform you that the Board of Directors at its meeting held today, i.e. on Tuesday, May 23, 2023, inter alia, has considered the financial results for the financial year ended March 31, 2023. Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ('SEBI Listing Regulations') we wish to inform you that the Board of Directors at its meeting held today, i.e. on Tuesday, May 23, 2023, inter alia, has considered the following: a)Financial results b)Recommendation of Final Dividend c)Annual General Meeting (AGM) and other matters The Board has recommended a final dividend at the rate of 30% i.e. Rs. 1.50/- per equity share of face value of Rs. 5/- each for the financial year ended March 31, 2023, subject to shareholders' approval at the ensuing Annual General Meeting ('AGM'). Pursuant to Regulation 42 of SEBI Listing Regulations, the Company has fixed Friday, July 7, 2023 as the record date for determining entitlement of members to final dividend for the financial year ended March 31, 2023. The dividend will be paid on or before September 8, 2023. (As Per BSE Announcement dated on 23.05.2023)
23-Apr-2023	26-Apr-2023	Issue of Debentures	BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/04/2023 inter alia to consider and approve Pursuant to Regulation 29(1)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday April 26 2023 inter alia to consider the issue of Secured Redeemable Non-Convertible Debentures on private placement basis investment in securities to be issued by Biocon Biologics Limited and provision of guarantees/put options amongst other matters. The above-mentioned information will also be available on website of the Company at www.biocon.com. Request you to take the above intimation on record. The Board of Directors of Biocon Limited at its meeting held today, i.e. on Wednesday, April 26, 2023, has approved the transaction for issuance of Secured, Redeemable, NCDs aggregating upto Rs. 500 crores on private placement basis to ESOF III Investment Fund managed by Edelweiss Alternate Asset Advisors Limited (EAAA) and EAAA. The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%. The proceeds from the NCDs will be further invested by Biocon Limited as OCDs in BBL on similar terms as the NCDs. The Board of Directors of BBL has considered and approved the execution of the transaction documents for issuance of CCDs of BBL aggregating upto Rs. 300 crores to Investors. CCDs will convert to 1:1 BBL shares with a contingent coupon to guarantee minimum 12% IRR. The consummation of above transactions are subject to customary regulatory approvals and conditions precedent. The Board Meeting commenced at 8:45 pm and concluded at 9:20 pm. (As per BSE Announcement Dated on 26/04/2023)
06-Jan-2023	14-Feb-2023	Quarterly Results	BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday February 14 2023 inter alia to approve and take on record the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31 2022 amongst other routine matters. Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ('SEBI Listing Regulations'), we wish to inform you that the Board of Directors at its meeting held today, i.e. on Tuesday, February 14, 2023 has approved the un-audited financial results (standalone and consolidated) of the Company prepared as per Indian Accounting Standard (Ind-AS) along with Limited Review Report thereon for the quarter and nine-months ended December 31, 2022. A copy of the unaudited financial results along with the Limited Review Report and is enclosed herewith. The above information will also be available on the website of the Company at www.biocon.com. Further, the Board Meeting commenced at 3:30 p.m. and concluded at 6:50 p.m. Kindly take the above information on record and acknowledge. Pursuant to Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations, 2015'), the Board of Directors at its meeting held today i.e. on February 14, 2023 has approved amendment in the Policy for Determination of Materiality for Disclosures, and below mentioned Key Managerial Personnel(s) have been authorized to determine materiality of an event or information and make necessary disclosures to the Stock Exchange(s): The revised policy on determination of materiality of events and information of the Company is available on the website of the Company. (As Per BSE Announcement Dated on 14.02.2023)
20-Oct-2022	14-Nov-2022	Quarterly Results	BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Monday November 14 2022 inter alia to approve and take on record the un-audited standalone and consolidated financial results for the quarter and half year ended September 30 2022 amongst other routine matters. The trading window fhas been closed from October 1 2022 to November 16 2022 (both days inclusive). The Company will organize an Earnings Conference Call for analysts/investors on Tuesday November 15 2022. This is further to our letter dated October 20, 2022, intimating the date of the Board meeting scheduled to be held on Monday, November 14, 2022. Please be informed that the Board at the aforesaid meeting shall also consider the issue of Redeemable, Non-Convertible Debentures and / or Commercial Paper on private placement basis, amongst other matters. The above-mentioned information will also be available on website of the Company at www.biocon.com. (As Per BSE Announcement Dated on 09/11/2022) Dear Sir/Madam, Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ('SEBI Listing Regulations') we wish to inform you that the Board of Directors at its meeting held today, i.e. on Monday, November 14, 2022, inter alia, has Approved the un-audited financial results (standalone and consolidated) of the Company prepared as per Indian Accounting Standard (Ind-AS) along with Limited Review Report thereon for the quarter and half-year ended September 30, 2022 along with few other matters. Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ('SEBI Listing Regulations') we wish to inform you that the Board of Directors at its meeting held today, i.e. on Monday, November 14, 2022, inter alia, has Approved the appointment of Mr. Peter Bains as an Additional Director (Category: Non-Executive, Independent Director) of the Company w.e.f. date of activation of DIN and registration in the Independent Director's databank maintained by the Indian Institute of Corporate Affairs (IICA), whichever is later (As Per BSE Announcement Dated on 14/11/2022) In continuation to our letter dated November 14, 2022 with regard to the Unaudited Financial Results for the quarter and half-year ended September 30, 2022, please find enclosed copies of newspaper advertisement published in Financial Express (English Language-All India Edition) and Vijayavani (Kannada-Bengaluru Edition) on November 16, 2022. The above information is also available on the website of the Company at www.biocon.com. (As Per BSE Announcement Dated on 16/11/2022)
01-Jul-2022	27-Jul-2022	Quarterly Results	BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2022 inter alia to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30 2022 amongst other matters. Financial results: Approved the un-audited financial results (standalone and consolidated) of the Company prepared as per Indian Accounting Standard (Ind-AS) along with Limited Review Report thereon for the quarter ended June 30, 2022. A copy of the un-audited financial results along with the Limited Review Report is enclosed herewith. The Board has considered the following: 1. Approved the un-audited financial results (standalone and consolidated)for the quarter ended June 30, 2022 2. Completion of tenure of Independent Directors namely Ms. Mary Harney (DIN: 05321964) and Mr. Daniel M Bradbury (DIN: 06599933), The Board Meeting commenced at 4:30 p.m. and concluded at 6:45 p.m. Completion of tenure of Independent Directors: Ms. Mary Harney (DIN: 05321964) and Mr. Daniel M Bradbury (DIN: 06599933), have completed their tenure with the Company as Independent Directors and consequently ceased to be Directors of the Company with effect from the conclusion of the Board meeting held today i.e. July 27, 2022. The Board of Directors and the Management of the Company express deep appreciation and gratitude to both the Directors for their extensive contribution and stewardship. (As Per BSE Announcement Dated on 27.07.2022)
04-Apr-2022	28-Apr-2022	Accounts	Audited Results & Dividend BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/04/2022 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, April 28, 2022, inter alia, to approve and take on record the audited standalone and consolidated financial results for the quarter and year ended March 31, 2022 and to consider recommendation of dividend, if any, amongst other routine matters. The trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading ('the Code') of the Company, has been closed from April 1, 2022 to April 30, 2022 (both days inclusive) in compliance with the provisions of the Code of the Company read with SEBI (Prohibition of Insider Trading) Regulations. Board Recommended a final dividend at the rate of 10% i.e. Re. 0.50/- per equity share of face value of Rs. 5/- each for the financial year ended March 31, 2022, subject to shareholders' approval at the ensuing Annual General Meeting (AGM') and record date for payment of final dividend is July 1, 2022. The dividend will be paid within 30 (thirty) days from the date of shareholders' approval at the ensuing 44th AGM (As Per BSE Bulletin Dated on 28.04.2022) Financial Results for the quarter and year ended March 31, 2022. Appointment of Ms. Naina Lal Kidwai as an Additional Director (Independent Director) of the Company. (As Per BSE Announcement dated on 28.04.2022) Newspaper Advertisement- Financial Results Quarter and Financial Year ended March 31, 2022 (As Per BSE Announcement dated on 01.05.2022)

1 2

LOGIN HERE

Biocon Ltd

Board Meeting